BMR.H Bradmer Pharmaceuticals

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A
VIOLATION OF U.S. SECURITIES LAW. 


Bradmer Pharmaceuticals Inc. ("Bradmer") (TSX VENTURE:BMR.H) announced today
that it has entered into a letter of intent dated February 18, 2014 with Alpha
Cancer Technologies Inc. ("Alpha"), a corporation existing under the laws of the
Province of Ontario, to complete a going-public transaction for Alpha (the
"Proposed Transaction").


It is currently anticipated that the Proposed Transaction will proceed by way of
an amalgamation of Bradmer and Alpha under the Business Corporations Act
(Ontario) (the "Amalgamation"), with the amalgamated entity (the "Resulting
Issuer") being named "Alpha Cancer Technologies Inc." (or such other name as
Alpha may determine). The Proposed Transaction, if completed, will constitute a
reverse take-over transaction pursuant to which the shareholders of Alpha will
hold a significant majority of the outstanding common shares of the Resulting
Issuer. The Proposed Transaction will be an arm's length transaction under the
policies of the TSX Venture Exchange (the "Exchange").


Alpha is a pre-clinical biopharmaceutical company (incorporated in September
2008) with a targeted chemotherapy delivery platform focused on the global
oncology market. Alpha holds the exclusive worldwide rights to recombinant human
Alpha Fetoprotein (AFP), a shuttle protein that targets AFP receptors found
almost exclusively on most solid and liquid cancer cells. Alpha's lead asset
ACT-901 combines AFP with paclitaxel, a generic chemotherapeutic drug, to target
cancer cells and more effectively deliver paclitaxel to cancerous tumors. Alpha
has the benefit of substantial knowledge and intellectual property investment by
its licensor in the development of AFP including an international patent
portfolio and an existing drug master manufacturing file deposited with the FDA,
with preclinical and human safety data in over 400 patients from Phase I and II
clinical trials of AFP. As a result, Alpha has significantly mitigated the risk
profile and has an expedited clinical development path to bring ACT-901 through
to commercialization. 


"While there have been advances in the treatment of cancer, there is no question
that cancer remains one of the largest areas of significant unmet medical need,"
commented Dr. Alan Ezrin, President and Chief Executive Officer of Bradmer.
"Alpha's targeted approach to the treatment of cancer has the potential to
become an important game changer using Alpha Fetoprotein to target chemotherapy
to AFP receptors which are expressed on most cancer cells. This targeted
approach holds great promise for enhanced delivery and increased therapeutic
effectiveness while minimizing non-target tissue side effects. As such, ACT-901
should significantly reduce or eliminate known side effects of paclitaxel." 


Upon completion of the Proposed Transaction, the Resulting Issuer will carry on
the business of Alpha. The parties intend that the Resulting Issuer will be
listed on the Exchange as a Life Sciences Issuer following completion of the
Proposed Transaction. 


The board of directors of the Resulting Issuer will consist of nominees of
Alpha; however, Bradmer shall be entitled to appoint Dr. Alan Ezrin (the
President and Chief Executive Officer of Bradmer) to the board of directors of
the Resulting Issuer. It is anticipated that the current executive officers of
Alpha, including Dr. Igor Sherman (President and Chief Executive Officer) and
Richard Potts (Chairman), will become executive officers of the Resulting
Issuer. 


In conjunction with, and prior to the closing of the Proposed Transaction, Alpha
intends to complete a private placement of Alpha Shares, 10% convertible notes,
subscription receipts and/or other securities convertible into Alpha Shares for
aggregate gross proceeds of between $7,000,000 and $10,000,000 (the "Private
Placement"), at an offering price or conversion price, as applicable, of $0.50
per Alpha Share. Euro Pacific Canada, Inc. has been engaged by Alpha to act as
agent for part of the Private Placement. Any convertible securities of Alpha
issued pursuant to the Private Placement will be converted to Alpha Shares
immediately prior to the completion of the Amalgamation. The pricing of the
Private Placement reflects a pre-money enterprise value for Alpha of
approximately $25,000,000. 


For the purposes of the Proposed Transaction, the deemed value of each
outstanding Bradmer Share will be $0.0632 (on a pre-Amalgamation basis).
Pursuant to the Amalgamation, it is anticipated that: (i) holders of Alpha
Shares (including purchasers under the Private Placement) will receive one
common share of the Resulting Issuer (an "Amalco Share") in exchange for each
outstanding Alpha Share (the "Alpha Exchange Ratio"); and (ii) holders of
Bradmer Shares will receive one Amalco Share in exchange for every 7.91
outstanding Bradmer Shares (the "Bradmer Exchange Ratio"). All outstanding
convertible securities of Alpha and Bradmer (including all outstanding options
or warrants) will be exchanged, subject to regulatory approval, for convertible
securities of the Resulting Issuer having economically equivalent terms and
conditions (having regard to the Alpha Exchange Ratio and Bradmer Exchange
Ratio, respectively). 


Following completion of the Amalgamation, assuming an aggregate of $10,000,000
is raised by Alpha pursuant to the Private Placement at an offering price of
$0.50 per Alpha Share: (i) existing shareholders of Bradmer will hold
approximately 3.4% of the outstanding Amalco Shares; (ii) existing shareholders
of Alpha will hold approximately 68.9% of the outstanding Amalco Shares; and
(iii) purchasers under the Private Placement will hold approximately 27.7% of
the outstanding Amalco Shares. 


The letter of intent is non-binding with respect to commercial terms, but
includes binding obligations typical in the circumstances, including those
relating to a period of exclusive dealing and confidentiality. The Proposed
Transaction is subject to a number of terms and conditions, including the
entering into by the parties of a definitive agreement with respect to the
Proposed Transaction on or prior to March 31, 2014 (such agreement to include
representations, warranties, conditions and covenants typical for a transaction
of this nature and magnitude), the completion of the Private Placement for
minimum gross proceeds to Alpha of $7,000,000 on or prior to March 31, 2014, the
completion of satisfactory due diligence investigations, the approval of the
directors of each of Bradmer and Alpha, the approval of the shareholders of
Bradmer, the approval of the shareholders of Alpha and the approval of the
Exchange and other applicable regulatory authorities. 


The Amalco Shares to be issued to holders of Alpha Shares (including those
issued under the Private Placement) and to the holders of Bradmer Shares
pursuant to the Amalgamation will be freely-tradeable, subject to the usual
restrictions contained in applicable securities legislation and any escrow
requirements that may be imposed contractually or pursuant to applicable stock
exchange rules or policies. 


In connection with the Proposed Transaction, Wildlaw Capital Markets Inc.
("WCM") is entitled to receive on closing of the Proposed Transaction: (i)
$200,000 payable either in cash, or at WCM's option, by the issuance to it of
400,000 Amalco Shares; (ii) warrants exercisable to acquire an aggregate of
500,000 Amalco Shares, at an exercise price of $0.50 per share, for a period 24
months following the closing of the Amalgamation; and (iii) 100,000 Amalco
Shares, pursuant to the terms and conditions of an agreement with Bradmer (as
amended based on negotiations with Alpha in connection with the entering into of
the letter of intent). 


Trading in Bradmer Shares will remain halted pending the satisfaction of all
applicable requirements of the Exchange. There can be no assurance that trading
in the Bradmer Shares will resume prior to the completion of the Proposed
Transaction. 


Further details concerning the Proposed Transaction and Alpha (including
financial information) will be set out in a further comprehensive press release,
if and when a definitive agreement is reached between the parties, in accordance
with the policies of the Exchange. 


All information contained in this press release relating to Alpha was provided
by Alpha to Bradmer for inclusion herein. Bradmer has not independently verified
such information and shall bear no liability for any misrepresentation contained
therein. 


Completion of the Proposed Transaction is subject to a number of conditions,
including, but not limited to, acceptance by the Exchange and shareholder
approval. The Proposed Transaction cannot close until the required shareholder
approval is obtained. There can be no assurance that the Proposed Transaction
will be completed as proposed or at all. 


Investors are cautioned that, except as disclosed in the management information
circular of Bradmer to be prepared in connection with the Proposed Transaction,
any information released or received with respect to the Proposed Transaction
may not be accurate or complete and should not be relied upon. Trading in the
securities of Bradmer should be considered to be highly speculative. 


The Exchange has in no way passed upon the merits of the Proposed Transaction
and has neither approved nor disapproved the contents of this press release. 


NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS
DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR
THE ADEQUACY OR ACCURACY OF THIS RELEASE. 


This press release does not constitute an offer to sell or the solicitation of
an offer to buy any securities in any jurisdiction. 


ANY SECURITIES REFERRED TO HEREIN WILL NOT BE REGISTERED UNDER THE U.S.
SECURITIES ACT OF 1933 (THE "1933 ACT") AND MAY NOT BE OFFERED OR SOLD IN THE
UNITED STATES OR TO A U.S. PERSON IN THE ABSENCE OF SUCH REGISTRATION OR AN
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE 1933 ACT. 


Forward-looking statements 

This news release contains certain "forward looking statements" including, for
example, statements relating to the completion of the Proposed Transaction
(including its proposed terms and conditions) and Private Placement. Such
forward-looking statements involve risks and uncertainties, both known and
unknown. The results or events depicted in these forward-looking statements may
differ materially from actual results or events. The forward-looking events and
circumstances discussed in this release, including the completion of the
Proposed Transaction (including its proposed terms and conditions) and the
Private Placement, may not occur by certain specified dates or at all and could
differ materially as a result of known and unknown risk factors and
uncertainties affecting Alpha, Bradmer or the Resulting Issuer, including risks
regarding the life sciences, biotechnology and pharmaceuticals industries,
failure to obtain regulatory or shareholder approvals, market conditions,
economic factors, the state of equity markets generally and risks associated
with growth, the protection of intellectual property and competition. Any
forward-looking statement speaks only as of the date of this news release and,
except as may be required by applicable securities laws, Bradmer and Alpha
disclaim any intent or obligation to update any forward-looking statement,
whether as a result of new information, future events or results or otherwise.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Bradmer Pharmaceuticals Inc.
Paul Van Damme
Chief Financial Officer
(416) 847-6905


Alpha Cancer Technologies Inc.
Richard Potts
Chairman
(416) 464-2768

Bradmer Pharmaceuticals (TSXV:BMR.H)
Historical Stock Chart
From May 2024 to Jun 2024

Bradmer Pharmaceuticals (TSXV:BMR.H)
Historical Stock Chart
From Jun 2023 to Jun 2024